PMID- 32641656
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20210222
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 59
IP  - 20
DP  - 2020 Oct 15
TI  - Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a 
      Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal 
      Hospital.
PG  - 2485-2490
LID - 10.2169/internalmedicine.5042-20 [doi]
AB  - Objective We investigated the continuation rate, safety and efficacy of treatment 
      with hydroxychloroquine (HCQ) in a retrospective cohort of systemic lupus 
      erythematosus (SLE) in a Japanese municipal hospital. Methods All of the patients 
      with SLE who started treatment with HCQ were included in this study. A 
      retrospective chart review was performed. Our primary outcomes were the 
      continuation rate of HCQ treatment for 1 year and adverse events (AEs) during the 
      treatment. We also investigated the efficacy of HCQ treatment in cases in which 
      treatment with immunosuppressive therapies remained unchanged for the preceding 
      six months. Results Forty-seven patients with SLE were included in this study. 
      Twenty-five patients (53.2%) had AEs. Eleven (64.7%) of the 17 patients who tried 
      the readministration of HCQ could continue HCQ treatment. The continuation rate 
      of HCQ for a period of 1 year was 78.3% (36 of 46 patients). The development of 
      cutaneous lesions was the most frequent adverse event (25.5%) followed by 
      gastrointestinal symptoms (8.5%). In the 16 cases in which the immunosuppressive 
      therapies remained unchanged for at least six months prior to starting HCQ 
      treatment, the SLE disease activity index, anti-DNA antibody, immune complex, and 
      serum complement activity significantly decreased over a period of 1 year, while 
      the prednisolone dose significantly decreased. Conclusion The continuation rate 
      of HCQ treatment was high in an SLE cohort of a Japanese municipal hospital. 
      Although more than half of the patients experienced AEs, the readministration of 
      HCQ was often successful. HCQ treatment provided benefits regarding the clinical 
      and immunological findings in Japanese patients with SLE, which would likely lead 
      to glucocorticoid tapering.
FAU - Hosokawa, Yohei
AU  - Hosokawa Y
AD  - Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Japan.
FAU - Oiwa, Hiroshi
AU  - Oiwa H
AD  - Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Antirheumatic Agents)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Adult
MH  - Antirheumatic Agents/*therapeutic use
MH  - Cohort Studies
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Female
MH  - Hospitals, Municipal/statistics & numerical data
MH  - Humans
MH  - Hydroxychloroquine/*adverse effects/*therapeutic use
MH  - Japan/epidemiology
MH  - Lupus Erythematosus, Systemic/*drug therapy/epidemiology/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC7662052
OTO - NOTNLM
OT  - Japanese
OT  - cohort study
OT  - continuation rate
OT  - hydroxychloroquine
OT  - safety
OT  - systemic lupus erythematosus
COIS- The authors state that they have no Conflict of Interest (COI).
EDAT- 2020/07/10 06:00
MHDA- 2021/02/23 06:00
PMCR- 2020/10/15
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/10/15 00:00 [pmc-release]
AID - 10.2169/internalmedicine.5042-20 [doi]
PST - ppublish
SO  - Intern Med. 2020 Oct 15;59(20):2485-2490. doi: 10.2169/internalmedicine.5042-20. 
      Epub 2020 Jul 7.